Faruqi & Faruqi Encourages Vistagen Investors to Reach Out
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 11 2026
0mins
Should l Buy VTGN?
Source: PRnewswire
- Legal Investigation Launched: Faruqi & Faruqi LLP is investigating potential claims against Vistagen Therapeutics, Inc., specifically targeting investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, aiming to protect investor rights.
- Investor Contact Information: Securities Litigation Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310) to discuss their legal options, ensuring timely action is taken.
- Class Action Deadline: Investors should note that the deadline to seek the role of lead plaintiff in the federal securities class action filed against Vistagen is March 16, 2026, underscoring the importance of prompt action.
- Legal Rights Reminder: Faruqi & Faruqi reminds investors that it is crucial to stay informed and exercise their legal rights to achieve the best outcomes in potential legal actions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VTGN?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VTGN
Wall Street analysts forecast VTGN stock price to rise
5 Analyst Rating
0 Buy
5 Hold
0 Sell
Hold
Current: 0.592
Low
0.90
Averages
0.97
High
1.00
Current: 0.592
Low
0.90
Averages
0.97
High
1.00
About VTGN
Vistagen Therapeutics, Inc. is a late clinical-stage biopharmaceutical company. The Company is leveraging a deep understanding of nose-to-brain neurocircuitry to develop and commercialize a new class of intranasal product candidates called pherines. Pherines specifically and selectively bind as agonists on peripheral receptors on human nasal chemosensory neurons and are designed to activate olfactory bulb-to-brain neurocircuits believed to regulate brain areas involved in behavior and autonomic nervous system activity. Its neuroscience product candidates include Fasedienol, Itruvone, PH15, PH80, and PH284. Fasedienol, its lead clinical-stage product candidate, is a synthetic neuroactive intranasal pherine in an ongoing U.S. registration-directed Phase III clinical development program for the acute treatment of anxiety in adults with SAD. Its neuroscience pipeline also includes an oral prodrug with potential to treat certain neurological conditions involving the NMDA receptor.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Faruqi & Faruqi Encourages Vistagen Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, which could significantly impact investors' legal options and potential recoveries.
- Direct Contact Encouraged: Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310), demonstrating the firm's dedication to client support and service.
- Class Action Context: This investigation is related to an existing federal securities class action against Vistagen, reflecting market concerns about the company's potential legal risks, which could negatively affect its stock price and investor confidence.
See More
Vistagen Class Action Notice for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiffs by March 16, 2026, to protect their rights in the class action lawsuit.
- Fee Structure: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected shareholders to participate.
- Case Background: The lawsuit alleges that Vistagen provided overly optimistic information regarding its drug fasedienol while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by March 16, 2026.
- Stock Price Plunge: Following the December 17, 2025 announcement that the PALISADE-3 Phase 3 study failed to show statistically significant improvement, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, indicating severe market pessimism regarding the company's future.
- Impact of Study Results: The failure to meet the primary endpoint and lack of significant difference between fasedienol and placebo on secondary endpoints could pose significant barriers to the company's future financing and product development efforts.
- Legal Background: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, highlights the potential for this case to attract broader legal and market scrutiny, emphasizing the ongoing risks associated with corporate misconduct.
See More
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statement Allegations: The complaint alleges that Vistagen made false and misleading statements, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies, which misled investors throughout the class period.
- Loss Recovery Opportunity: Investors suffered damages when the truth about Vistagen emerged, and the Schall Law Firm encourages affected shareholders to join the lawsuit to recover their losses, indicating potential significant financial liability for the company in the class action.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to contact them via phone or website to ensure proper legal representation in the class action and avoid being an absent class member.
See More
Vistagen Therapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Vistagen Therapeutics (NASDAQ: VTGN), encouraging those who purchased shares during the class period from April 1, 2024, to December 16, 2025, to contact the firm regarding potential lead plaintiff appointment.
- Poor Trial Results: On December 17, 2025, Vistagen announced that its PALISADE-3 trial for fasedienol, aimed at treating social anxiety disorder, failed to show statistically significant improvement on its primary endpoint, causing the stock price to plummet from $4.36 to $0.86, a decline exceeding 80%.
- Shareholder Registration Deadline: Shareholders must register by March 16, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress through portfolio monitoring software.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to false statements or omissions by companies, emphasizing the need for responsible business practices.
See More
Vistagen Class Action Notice for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to participate in the class action and protect their rights.
- Fee Structure: Investors joining the Vistagen class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors and encourages more victims to seek compensation.
- Case Background: The lawsuit alleges that Vistagen misled investors regarding its drug fasedienol's development, claiming positive outcomes from clinical trials while concealing significant adverse facts related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and strength in handling such cases.
See More
Faruqi & Faruqi Encourages Vistagen Investors to Reach Out
- Legal Investigation Launched: Faruq & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc., particularly for investors who purchased or acquired securities between April 1, 2024, and December 16, 2025, highlighting the firm's commitment to protecting investor rights.
- Investor Rights Reminder: The firm reminds investors that March 16, 2026, is the deadline to seek the role of lead plaintiff in a federal securities class action, which could significantly impact investors' legal options and potential recoveries.
- Direct Contact Encouraged: Partner Josh Wilson encourages affected investors to contact him directly at 877-247-4292 or 212-983-9330 (Ext. 1310), demonstrating the firm's dedication to client support and service.
- Class Action Context: This investigation is related to an existing federal securities class action against Vistagen, reflecting market concerns about the company's potential legal risks, which could negatively affect its stock price and investor confidence.
See More
Vistagen Class Action Notice for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Vistagen common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiffs by March 16, 2026, to protect their rights in the class action lawsuit.
- Fee Structure: Investors joining the Vistagen class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages more affected shareholders to participate.
- Case Background: The lawsuit alleges that Vistagen provided overly optimistic information regarding its drug fasedienol while concealing significant adverse facts related to the PALISADE-3 clinical trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling similar cases.
See More
Vistagen Faces Class Action Lawsuit Impacting Stock Price
- Class Action Filed: Pomerantz LLP has announced a class action lawsuit against Vistagen Therapeutics, alleging securities fraud and other unlawful business practices, with investors advised to apply as Lead Plaintiff by March 16, 2026.
- Stock Price Plunge: Following the December 17, 2025 announcement that the PALISADE-3 Phase 3 study failed to show statistically significant improvement, Vistagen's stock price plummeted by 80.25% to close at $0.861 per share, indicating severe market pessimism regarding the company's future.
- Impact of Study Results: The failure to meet the primary endpoint and lack of significant difference between fasedienol and placebo on secondary endpoints could pose significant barriers to the company's future financing and product development efforts.
- Legal Background: Pomerantz LLP, a premier firm in securities class litigation with over 85 years of experience, highlights the potential for this case to attract broader legal and market scrutiny, emphasizing the ongoing risks associated with corporate misconduct.
See More
Vistagen Therapeutics Faces Class Action Lawsuit for Securities Violations
- Class Action Reminder: The Schall Law Firm is reminding investors of a class action lawsuit against Vistagen Therapeutics for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between April 1, 2024, and December 16, 2025, with a deadline to contact the firm by March 16, 2026.
- False Statement Allegations: The complaint alleges that Vistagen made false and misleading statements, creating a false impression of likely Phase 3 success for its fasedienol drug candidate by downplaying the risks of failure in clinical studies, which misled investors throughout the class period.
- Loss Recovery Opportunity: Investors suffered damages when the truth about Vistagen emerged, and the Schall Law Firm encourages affected shareholders to join the lawsuit to recover their losses, indicating potential significant financial liability for the company in the class action.
- Legal Consultation Services: The Schall Law Firm offers free legal consultations, allowing investors to contact them via phone or website to ensure proper legal representation in the class action and avoid being an absent class member.
See More
Vistagen Therapeutics Shareholder Notice Issued
- Lawsuit Notice Issued: The Gross Law Firm has issued a notice to shareholders of Vistagen Therapeutics (NASDAQ: VTGN), encouraging those who purchased shares during the class period from April 1, 2024, to December 16, 2025, to contact the firm regarding potential lead plaintiff appointment.
- Poor Trial Results: On December 17, 2025, Vistagen announced that its PALISADE-3 trial for fasedienol, aimed at treating social anxiety disorder, failed to show statistically significant improvement on its primary endpoint, causing the stock price to plummet from $4.36 to $0.86, a decline exceeding 80%.
- Shareholder Registration Deadline: Shareholders must register by March 16, 2026, to participate in the class action lawsuit, and upon registration, they will receive updates on the case's progress through portfolio monitoring software.
- Law Firm Background: The Gross Law Firm is a nationally recognized class action law firm committed to protecting investors' rights who have suffered losses due to false statements or omissions by companies, emphasizing the need for responsible business practices.
See More
Vistagen Class Action Notice for Investors
- Litigation Timeline: Rosen Law Firm reminds investors who purchased Vistagen Therapeutics (NASDAQ:VTGN) common stock between April 1, 2024, and December 16, 2025, that they must apply to be lead plaintiff by March 16, 2026, to participate in the class action and protect their rights.
- Fee Structure: Investors joining the Vistagen class action will incur no upfront costs, as the law firm operates on a contingency fee basis, which alleviates the financial burden on investors and encourages more victims to seek compensation.
- Case Background: The lawsuit alleges that Vistagen misled investors regarding its drug fasedienol's development, claiming positive outcomes from clinical trials while concealing significant adverse facts related to the PALISADE-3 trial, resulting in investor losses when the truth emerged.
- Law Firm Credentials: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, and was ranked first in 2017 for the number of securities class action settlements, demonstrating its expertise and strength in handling such cases.
See More
